Drug Profile


Alternative Names: MM-141

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adimab
  • Developer Adimab; Merrimack Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours
  • Preclinical Ovarian cancer

Most Recent Events

  • 09 Aug 2017 Merrimack completes enrolment in the phase II CARRIE trial in Pancreatic cancer
  • 19 Jun 2017 Merrimack Pharmaceuticals completes enrolment in the phase II CARRIE trial for Pancreatic cancer (Combination therapy, Metastatic disease, First-line therapy) in USA, Spain, Canada, Germany, Poland and United Kingdom (Parenteral)
  • 15 Nov 2016 Phase-I trials in Solid-tumours (Late-stage disease) in France and USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top